James A. Posey III, MD

James A. Posey III, MD

Contact Dr. Posey III

1025 Walnut Street
Suite 700
Philadelphia, PA 19107

(215) 503-6442
(215) 503-3408 fax

Most Recent Peer-reviewed Publications

  1. Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: An alternative to the current RECIST-defined response
  2. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity
  3. Multiregion whole-exome sequencing of matched primary and metastatic tumors revealed genomic heterogeneity and suggested polyclonal seeding in colorectal cancer metastasis
  4. Pancreatic cancer survivors’ preferences, barriers, and facilitators related to physical activity and diet interventions
  5. RNA sequencing of pancreatic adenocarcinoma tumors yields novel expression patterns associated with long-term survival and reveals a role for ANGPTL4
  6. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone
  7. Esophageal and esophagogastric junction cancers, Version 1.2015
  8. Hepatobiliary cancers, version 2.2014
  9. Quantitative perfusion- and diffusion-weighted magnetic resonance imaging of gastrointestinal cancers treated with multikinase inhibitors: A pilot study
  10. Pancreatic adenocarcinoma: A pilot study of quantitative perfusion and diffusion-weighted breath-hold magnetic resonance imaging
  11. Erratum to: Pancreatic adenocarcinoma: a pilot study of quantitative perfusion and diffusion-weighted breath-hold magnetic resonance imaging (Abdom Imaging (2014) 39, (744–752) 10.1007/s00261-014-0107-z)
  12. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases
  13. Gastric cancer, version 2.2013
  14. Esophageal and esophagogastric junction cancers
  15. A phase i study evaluating the role of the anti-epidermal growth factor receptor (EGFR) antibody cetuximab as a radiosensitizer with chemoradiation for locally advanced pancreatic cancer
  16. Resectability of pancreatic adenocarcinoma in patients with locally advanced disease downstaged by preoperative therapy: A challenge for MDCT
  17. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)
  18. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: A phase II trial
  19. Gastric cancer: Clinical practice guidelines in oncology™
  20. Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers